PC
MDGL icon

Pier Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pier Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-37,654
Closed -$4.24M – 110
2018
Q4 		$4.24M Buy
37,654
+17,300
+85% +$2.68M 0.84% 65
2018
Q3 		$4.36M Buy
+20,354
New +$5.11M 0.55% 93

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pier Capital's MDGL Position: Q1 2019 in Review

Pier Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2019, closing a stake of 37,654 shares — an estimated $4.24M sold.

Pier Capital first reported a position in MDGL in Q3 2018 and held it in 2 quarters. The position peaked at $4.36M in Q3 2018. 135 funds tracked by Wall St. Rank hold MDGL as of Q1 2019.

  • Pier Capital reported no remaining Madrigal Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Pier Capital sold 37,654 Madrigal Pharmaceuticals shares in Q1 2019, an estimated $4.24M.
  • Pier Capital first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Pier Capital's Madrigal Pharmaceuticals position peaked at $4.36M in Q3 2018.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2019.

Based on Pier Capital's 13F filing for Q1 2019, filed 24 Apr 2019.